Hemarthrosis Treatment Market By Condition / Etiology Type (Hemophilia A Hemarthrosis, Hemophilia B Hemarthrosis, Other Coagulopathies & Rare Bleeding Disorders, Ligamentous & Meniscal Injury-Related Hemarthrosis, Intra-Articular Fracture-Related Hemarthrosis, Postoperative Hemarthrosis (Joint Replacement Complications)); By Treatment & Therapy Type (Plasma-Derived Factor Concentrates, Recombinant Factor Concentrates, Adjunctive Pharmacological Agents, Novel & Emerging Biologics, Joint Aspiration (Arthrocentesis), Geniculate Artery Embolization (GAE), Surgical Synovectomy, Conservative Management (RICE and Supportive Care)); By Management Strategy / Regimen (Prophylaxis Therapy, On-Demand (Episodic) Therapy); By Distribution Channel (Hospital Pharmacies & Inpatient Centers, Specialty Pharmacies & Hemophilia Treatment Centers (HTCs)); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Rising Hemophilia Cases, Recurrent Joint Bleeding, and Advanced Treatment Technologies Shaping the Hemarthrosis Treatment Market?

The Global Hemarthrosis Treatment Market was estimated at USD 1.11 billion in 2025 and projected to reach USD 1.49 billion by 2032, expanding at a CAGR of 4.33% during 2026–2032, according to Strategic Market Research.

 

The Hemarthrosis Treatment Market addresses patients experiencing bleeding inside joints, particularly those with hemophilia, recurrent joint hemorrhage, and bleeding-related joint damage. According to the CDC, approximately 33,000 males in the United States have hemophilia, representing a population at risk of joint bleeding. A 2024 Yale University study found that 28.6% of 70 patients with mild hemophilia had experienced joint bleeding, including 13 patients with traumatic bleeding and 7 with spontaneous bleeding. Globally, a UK registry study involving 2,238 patients with severe hemophilia reported annual hemarthrosis prevalence of 59.9% among adults with hemophilia A and 42.1% among adults with hemophilia B.

 

Recurrent joint bleeding creates substantial treatment requirements and increases the risk of permanent joint damage. World Federation of Hemophilia guidelines indicate that 70–80% of bleeding episodes in hemophilia occur in joints, particularly the knees, ankles, and elbows. A 2024 Chinese study involving 185 hemophilia B patients reported that 71.4% had experienced joint hemorrhage, while 64.4% of those with joint bleeding had developed target joints, indicating repeated bleeding in affected joints.

 

Treatment effectiveness represents an important factor influencing the Hemarthrosis Treatment Market. FDA-reviewed clinical evidence for Qfitlia (fitusiran) demonstrated 6.2 treated joint bleeding episodes annually with preventive therapy, compared with 21.6 episodes under on-demand clotting factor treatment, representing a 71% reduction. The FDA's March 2025 approval of Qfitlia expanded preventive treatment options for eligible hemophilia A and B patients.

 

Overall, market opportunities center on preventing recurrent hemarthrosis, expanding access to clotting factor replacement and non-factor preventive therapies, and treating bleeding-related joint complications. Improved prophylaxis could shift pharmaceutical expenditure toward long-term bleeding prevention while reducing acute treatment episodes, chronic joint inflammation, and progressive joint damage.

 

Which Subsegments Lead the Hemarthrosis Treatment Market, and Where Are the Fastest-Growing Revenue Opportunities Emerging?

By Condition / Etiology Type: Hemophilia A Dominates, While Traumatic Joint Injuries Accelerate Treatment Demand

Leading Subsegment – Hemophilia A Hemarthrosis

Hemophilia A Hemarthrosis account for an estimated 59% of the Hemarthrosis Treatment Market, valued at USD 655 million in 2025, and is projected to grow at a CAGR of 3.51% during 2026–2032. Hemophilia A, characterized by clotting factor VIII deficiency, is a leading cause of recurrent bleeding into joint cavities, particularly the knees, elbows, and ankles. Repeated joint bleeding increases the need for factor VIII replacement therapy, non-factor prophylactic treatments, and long-term management to prevent progressive joint damage and hemophilic arthropathy.

Fastest-Growing Subsegment – Ligamentous & Meniscal Injury-Related Hemarthrosis

Ligamentous and meniscal injuries account for an estimated 12% of the Hemarthrosis Treatment Market, valued at USD 133 million in 2025, and are projected to register the fastest CAGR of 6.21% during 2026–2032. Anterior cruciate ligament (ACL) tears and meniscal injuries are major causes of acute knee hemarthrosis. The vascularized peripheral 3–5 mm of the meniscus and blood-rich ACL tissue contribute to intra-articular bleeding following injury, increasing the need for joint aspiration, arthroscopic interventions, ligament reconstruction, and postoperative management.

 

By Treatment & Therapy Type: Recombinant Factors Lead Revenue, While Vascular Interventions Show Faster Expansion

Leading Subsegment – Recombinant Factor Concentrates

Recombinant Factor Concentrates account for an estimated 38% share of the Hemarthrosis Treatment Market, valued at USD 422 million in 2025, and are projected to grow at a CAGR of 3.40% during 2026–2032. Recombinant factor VIII, factor IX, and activated factor VII play an important role in controlling acute joint bleeding and preventing recurrent hemarthrosis among patients with hemophilia. Their use in prophylactic replacement therapy helps reduce bleeding episodes, preserve joint function, and limit progressive joint damage associated with repeated bleeding.

Fastest-Growing Subsegment – Geniculate Artery Embolization (GAE)

Geniculate Artery Embolization (GAE) accounts for an estimated 3% share of the Hemarthrosis Treatment Market, valued at USD 33 million in 2025, and is projected to register the fastest CAGR of 8.90% during 2026–2032. Originally developed to manage recurrent knee hemarthrosis, GAE is a minimally invasive, catheter-based interventional radiology procedure that selectively blocks abnormal blood vessels responsible for joint bleeding. Its growing clinical application in managing persistent bleeding following knee replacement surgery and its subsequent adoption in chronic knee osteoarthritis are expanding treatment opportunities.

 

By Management Strategy / Regimen: Preventive Treatment Leads Both Market Share and Growth

Leading and Fastest-Growing Subsegment – Prophylaxis Therapy

Prophylaxis therapy dominates the Hemarthrosis Treatment Market with an estimated 67% market share, representing USD 744 million in 2025, and is projected to register the fastest treatment regimen CAGR of 4.93% during 2026–2032. Recognized as the gold standard for managing severe hemophilia, prophylaxis involves regular administration of clotting factor replacement or non-factor therapies to maintain protective hemostatic activity. Its widespread clinical adoption reflects its effectiveness in preventing recurrent joint bleeding, reducing hemarthrosis episodes, and limiting progressive joint damage and long-term hemophilic arthropathy.

 

By Distribution Channel: Specialty Pharmacies and Hemophilia Treatment Centers Lead Treatment Access

Leading and Fastest-Growing Subsegment – Specialty Pharmacies & Hemophilia Treatment Centers (HTCs)

Specialty Pharmacies and Hemophilia Treatment Centers (HTCs) collectively accounted for an estimated 57% share of the global Hemarthrosis Treatment Market, valued at USD 633 million in 2025, and are projected to register the fastest CAGR of 4.84% during 2026–2032. HTCs provide specialized care for hemophilia-related joint bleeding through multidisciplinary treatment, clotting factor replacement, and long-term joint health monitoring. Specialty pharmacies complement clinical care by ensuring access to prescribed factor concentrates, non-factor therapies, and home infusion support, strengthening treatment continuity and helping prevent recurrent hemarthrosis and progressive joint damage.

 

By Geography: North America Leads Revenue, While Asia-Pacific Offers Faster Growth Potential

Leading Regional Subsegment – North America

North America dominates the Hemarthrosis Treatment Market, accounting for an estimated 39% global market share, valued at USD 433 million in 2025, and is projected to expand at a CAGR of 3.76% during 2026–2032. Treatment adoption is supported by specialized hemophilia treatment centers, multidisciplinary orthopedic care, and access to advanced coagulation therapies. The growing utilization of factor replacement therapies, non-factor prophylactic treatments, joint imaging, and minimally invasive orthopedic interventions strengthens clinical management of recurrent joint bleeding, particularly among patients with hemophilia and anticoagulant-associated hemarthrosis.

Fastest-Growing Regional Subsegment – Asia-Pacific

Asia-Pacific Hemarthrosis Treatment Market accounted for an estimated 24% of global market share, valued at USD 266 million in 2025, and is projected to register the fastest regional CAGR of 5.76% during 2026–2032. Treatment adoption varies considerably across the region, with Japan, South Korea, and Australia benefiting from established hemophilia care networks, while China and India are expanding access to clotting factor replacement therapies, prophylactic treatment, and specialized hematology services. Improving hemophilia diagnosis and increasing availability of advanced therapies are supporting regional market expansion.

 

Which Companies Are Leading the Hemarthrosis Treatment Market Through Advanced Hemophilia Therapies and Joint Bleeding Prevention?

F. Hoffmann-La Roche (Chugai): Advancing Joint Bleeding Prevention with Hemlibra

F. Hoffmann-La Roche is a leading pharmaceutical participant in hemophilia-associated hemarthrosis prevention, supported by its bispecific antibody therapy Hemlibra (emicizumab). The treatment mimics the function of activated factor VIII, supporting clot formation and reducing bleeding episodes in patients with hemophilia A.

According to Roche's 2025 financial results, Hemlibra generated CHF 4.754 billion in global sales, recording 11% growth at constant exchange rates. The United States contributed CHF 2.665 billion, while Europe accounted for CHF 1.002 billion. Hemlibra's commercial performance reflects the growing importance of preventive biologic therapies in hemophilia management. Its subcutaneous administration and demonstrated ability to reduce treated joint bleeding support long-term treatment adoption and recurring pharmaceutical revenue.

These sales cover Hemlibra's overall hemophilia A indication and should not be interpreted as revenue exclusively attributable to hemarthrosis treatment.

Other Key Companies and Their Roles in Hemarthrosis Treatment

• Takeda Pharmaceutical Company: Supplies ADVATE, ADYNOVATE and FEIBA, supporting factor VIII replacement and bleeding management in hemophilia patients.

• Sanofi: Commercializes ALTUVIIIO, a once-weekly extended-half-life factor VIII therapy that generated EUR 1.16 billion in 2025 sales, supporting prevention of joint bleeding in hemophilia A.

• Pfizer Inc.: Develops and commercializes HYMPAVZI (marstacimab), an anti-TFPI antibody therapy designed to reduce bleeding episodes in hemophilia A and B.

• Novo Nordisk: Offers NovoEight and Esperoct for factor VIII replacement and Alhemo (concizumab) for non-factor prophylaxis in eligible hemophilia patients.

• CSL Behring: Provides recombinant and plasma-derived clotting factor therapies, including AFSTYLA and IDELVION, supporting long-term bleeding prevention.

• Bayer Healthcare: Supplies Kovaltry and Jivi, recombinant factor VIII therapies used in hemophilia A bleeding management and prophylaxis.

• BioMarin Pharmaceutical: Developed ROCTAVIAN, a gene therapy for eligible adults with severe hemophilia A, although its commercial contribution is limited following the company's decision to discontinue commercialization.

 

Analyst Commentary: How Will Preventive Biologics and Joint Preservation Shape Future Treatment?

The Hemarthrosis Treatment Market is shifting from episodic bleeding management toward preventive therapies that reduce recurrent joint bleeding and long-term joint damage. The strongest growth opportunities lie in extended-half-life clotting factors, non-factor prophylactic biologics, and minimally invasive interventions for persistent hemarthrosis. Increasing emphasis on early treatment, joint preservation, and individualized bleeding prevention is expected to accelerate the adoption of advanced therapies, while improved access to specialized hemophilia care will support sustained market expansion.

 

Hemarthrosis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.11 Billion
Revenue Forecast in 2032	USD 1.49 Billion
Overall Growth Rate	CAGR of 4.33% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Condition / Etiology Type, By Treatment & Therapy Type, By Management Strategy / Regimen, By Distribution Channel, By Geography
By Condition / Etiology Type	Hemophilia A Hemarthrosis, Hemophilia B Hemarthrosis, Other Coagulopathies & Rare Bleeding Disorders, Ligamentous & Meniscal Injury-Related Hemarthrosis, Intra-Articular Fracture-Related Hemarthrosis, Postoperative Hemarthrosis (Joint Replacement Complications)
By Treatment & Therapy Type	Plasma-Derived Factor Concentrates, Recombinant Factor Concentrates, Adjunctive Pharmacological Agents, Novel & Emerging Biologics, Joint Aspiration (Arthrocentesis), Geniculate Artery Embolization (GAE), Surgical Synovectomy, Conservative Management (RICE and Supportive Care)
By Management Strategy / Regimen	Prophylaxis Therapy, On-Demand (Episodic) Therapy
By Distribution Channel	Hospital Pharmacies & Inpatient Centers, Specialty Pharmacies & Hemophilia Treatment Centers (HTCs)
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	High prevalence of hemophilia-associated joint bleeding, recurrent hemarthrosis and progressive joint damage, increasing adoption of prophylaxis therapy, growing use of recombinant factor concentrates, expansion of non-factor preventive biologics, FDA approval of Qfitlia (fitusiran), increasing demand for long-term bleeding prevention, development of minimally invasive interventions such as geniculate artery embolization, and expanding access to specialized hemophilia treatment centers and specialty pharmacies
Customization Option	Available upon request